Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

Leuk Lymphoma. 2016;57(1):226-9. doi: 10.3109/10428194.2015.1046863. Epub 2015 Jun 18.

Affiliations

¹ a Department of Internal Medicine I , University Hospital of Schleswig-Holstein , Luebeck , Germany.
² b Department of Pathology , Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein , Luebeck , Germany.
³ c Department of Radiation Oncology , University Hospital of Schleswig-Holstein , Luebeck , Germany.

PMID: 25947035
DOI: 10.3109/10428194.2015.1046863

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Alkylating / administration & dosage*
Genes, ras*
Hematopoietic Stem Cell Transplantation*
Humans
Kaplan-Meier Estimate
Melphalan / administration & dosage*
Multiple Myeloma / genetics*
Multiple Myeloma / mortality
Multiple Myeloma / therapy*
Mutation*
Prognosis
Transplantation Conditioning*
Transplantation, Autologous*
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Melphalan